Stock Overview

Kymera Therapeutics Inc (KYMR)

NASDAQ · Healthcare · Biotechnology

Kymera Therapeutics Inc is a Healthcare company with a market capitalization of $9.32B.

Market Cap
$9.32B
Price/Sales
88.8
Price/Book
6.3
EV/EBITDA
-10.0
Beta
1.95
EPS (TTM)
$-3.25
Profit Margin
-612.2%
ROE
-24.1%
Short % of Float
15.0%
Days to Cover
14.7
52W High
$119.35
52W Low
$40.69

5-Year Price History

Latest Annual Financials · FY ending December 31, 2025

Revenue
$39.20M
Gross Profit
$39.20M
Operating Income
-$349.40M
Net Income
-$311.40M
Free Cash Flow
-$234.34M
Total Debt
$13.76M
Cash & Equivalents
$357.01M
Shareholder Equity
$1.58B

Recent Quarterly Earnings (EPS)

QuarterReportedActual EPSEstimateSurprise
Q1 2026April 30, 2026$-0.71$-0.86+17.4%
Q4 2025February 26, 2026$-0.97$-0.77-26.0%
Q3 2025November 4, 2025$-0.94$-0.78-20.5%
Q2 2025August 11, 2025$-0.95$-0.80-18.8%
Q1 2025May 9, 2025$-0.82$-0.91+9.9%
Q4 2024February 27, 2025$-0.89$-0.79-12.9%

Short Interest

FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.

SettlementShares Short% of Shares OutDays to CoverChange
July 15, 20269,900,46910.15%14.7-2.4%
June 30, 202610,146,00310.40%5.3+1.8%
June 15, 20269,962,82310.21%15.6-1.4%
May 29, 202610,103,69810.36%20.6+1.0%
May 15, 202610,004,36310.26%21.3+3.3%
April 30, 20269,687,5989.93%18.8+0.7%
April 15, 20269,622,45211.40%19.5-7.5%
March 31, 202610,402,72212.33%14.6+4.3%

Other Biotechnology Stocks

Frequently Asked Questions

What is Kymera Therapeutics Inc's market cap?

As of August 13, 2026, Kymera Therapeutics Inc (KYMR) has a market capitalization of $9.32B.

Does Kymera Therapeutics Inc pay a dividend?

Kymera Therapeutics Inc does not currently pay a dividend.

What sector is KYMR in?

Kymera Therapeutics Inc is in the Healthcare sector, specifically the Biotechnology industry.

What is Kymera Therapeutics Inc's short interest?

As of the July 15, 2026 FINRA settlement, 9,900,469 KYMR shares were sold short, or 10.15% of shares outstanding. Days to cover: 14.7. FINRA publishes short interest twice a month, about nine business days after each settlement date.

What was Kymera Therapeutics Inc's revenue?

In its latest reported fiscal year (ending December 31, 2025), Kymera Therapeutics Inc reported revenue of $39.20M and net income of -$311.40M.

Ask your own questions about KYMR

Try mrmarket.ai free

Data as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.